Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Otorhinolaryngology

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 135 articles:
HTML format



Single Articles


    July 2021
  1. TRENDOWSKI MR, Baedke JL, Sapkota Y, Travis LB, et al
    Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
    Cancer. 2021 Jul 19. doi: 10.1002/cncr.33775.
    PubMed     Abstract available


  2. LIU Z, Li H, Yu KJ, Xie SH, et al
    Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma.
    Cancer. 2021 Jul 7. doi: 10.1002/cncr.33552.
    PubMed     Abstract available


    June 2021
  3. WITHROW DR, Devesa SS, Deapen D, Petkov V, et al
    Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004-2017.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33553.
    PubMed     Abstract available


  4. FU TS, Scheffler P, Forner D, Noel CW, et al
    A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33653.
    PubMed     Abstract available


    May 2021
  5. RUAN X, Liang JH, Pan Y, Cai R, et al
    Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33626.
    PubMed     Abstract available


  6. XIAO C, Beitler JJ, Peng G, Levine ME, et al
    Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.
    Cancer. 2021 May 24. doi: 10.1002/cncr.33641.
    PubMed     Abstract available


  7. WEISS JM
    Surgery alone for transorally resected human papillomavirus-driven head and neck cancer-Can we de-intensify adjuvant therapy to 0 Gy and 0 mg/m(2) ?
    Cancer. 2021 May 6. doi: 10.1002/cncr.33610.
    PubMed     Abstract available


    April 2021
  8. CHEN Y, Chang ET, Liu Q, Cai Y, et al
    Occupational exposures and risk of nasopharyngeal carcinoma in a high-risk area: A population-based case-control study.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33536.
    PubMed     Abstract available


  9. THOMAS GR
    Racial disparity in head and neck cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33555.
    PubMed    


  10. VOORA RS, Kotha NV, Kumar A, Qiao EM, et al
    Association of Race and Health Care System With Disease Stage and Survival in Veterans With Larynx Cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33557.
    PubMed     Abstract available


    February 2021
  11. DE BREE R, de Keizer B
    Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33443.
    PubMed    


  12. NOEL CW, Forner D, Goldstein DP, Metser U, et al
    Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33446.
    PubMed     Abstract available


  13. KIONG KL, Yao CMKL, Lin FY, Bell D, et al
    Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33471.
    PubMed     Abstract available


  14. SHEWALE JB, Pickard RKL, Xiao W, Jiang B, et al
    Independent association of marijuana use and poor oral hygiene with HPV-negative but not HPV-positive head and neck squamous cell carcinomas.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33440.
    PubMed     Abstract available


  15. WANG SM, Freedman ND, Katki HA, Matthews C, et al
    Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort.
    Cancer. 2021 Feb 22. doi: 10.1002/cncr.33427.
    PubMed     Abstract available


  16. LYDIATT WM
    Head and neck cancer staging: Balancing innovation with consistency.
    Cancer. 2021 Feb 17. doi: 10.1002/cncr.33415.
    PubMed    


  17. PRINTZ C
    Study adds evidence to link between gum disease and cancer risk: Researchers observe connection with gastric, esophageal cancer.
    Cancer. 2021;127:495-496.
    PubMed    


    January 2021
  18. YAO CMKL, Fu S, Tam S, Kiong KL, et al
    Impact of provider type and number of providers on surveillance testing among survivors of head and neck cancers.
    Cancer. 2021 Jan 20. doi: 10.1002/cncr.33402.
    PubMed     Abstract available


  19. LIN YT, Wang HC, Tsai MH, Su YY, et al
    Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.
    Cancer. 2021 Jan 6. doi: 10.1002/cncr.33391.
    PubMed     Abstract available


    December 2020

  20. Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study.
    Cancer. 2020 Dec 21. doi: 10.1002/cncr.33320.
    PubMed     Abstract available


  21. AMIT M, Liu C, Gleber-Netto FO, Kini S, et al
    Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2020 Dec 15. doi: 10.1002/cncr.33373.
    PubMed     Abstract available


    November 2020
  22. KAWASAKI M, Ikeda Y, Ikeda E, Takahashi M, et al
    Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer.
    Cancer. 2020 Nov 6. doi: 10.1002/cncr.33316.
    PubMed     Abstract available


    October 2020
  23. MORGAN RL, Eguchi MM, McDermott J, Mueller AC, et al
    Comparative effectiveness of posttreatment imaging modalities for Medicare patients with advanced head and neck cancer.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33244.
    PubMed     Abstract available


  24. LIU W, Qdaisat A, Ferrarotto R, Fuller CD, et al
    Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
    Cancer. 2020 Oct 21. doi: 10.1002/cncr.33283.
    PubMed     Abstract available


  25. SWIECICKI PL, Bellile EL, Brummel CV, Brenner JC, et al
    Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33226.
    PubMed     Abstract available


  26. ZHANG N, Li Y, Chang X, Lei F, et al
    Long-term effectiveness of one-time endoscopic screening for esophageal cancer: A community-based study in rural China.
    Cancer. 2020;126:4511-4520.
    PubMed     Abstract available


  27. ZAKERI K, Rotolo F, Lacas B, Vitzthum LK, et al
    Predictive classifier for intensive treatment of head and neck cancer.
    Cancer. 2020 Oct 5. doi: 10.1002/cncr.33212.
    PubMed     Abstract available


    September 2020
  28. G V REDDY N, Singh A, Subash A
    Preservation of spinal accessory and level 2b-sparing neck dissection: The balance beyond oncology and functionality.
    Cancer. 2020 Sep 17. doi: 10.1002/cncr.33166.
    PubMed    


  29. DZIEGIELEWSKI PT, Seikaly H
    Reply to Preservation of spinal accessory and level 2b-sparing neck dissection: The balance beyond oncology and functionality.
    Cancer. 2020 Sep 17. doi: 10.1002/cncr.33164.
    PubMed    


  30. HU J, Huang Q, Gao J, Guan X, et al
    Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Cancer. 2020 Sep 15. doi: 10.1002/cncr.33197.
    PubMed     Abstract available


  31. REYES-GIBBY CC, Wang J, Zhang L, Peterson CB, et al
    Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33161.
    PubMed     Abstract available


    August 2020
  32. DE ALMEIDA JR, Noel CW, Forner D, Zhang H, et al
    Development and validation of a surgical prioritization and ranking tool and navigation aid for head and neck cancer (SPARTAN-HN) in a scarce resource setting: Response to the COVID-19 pandemic.
    Cancer. 2020 Aug 11. doi: 10.1002/cncr.33114.
    PubMed     Abstract available


  33. HONG MH, Heo SG, Lee YG, Kim HS, et al
    Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
    Cancer. 2020 Aug 4. doi: 10.1002/cncr.33123.
    PubMed     Abstract available


    July 2020
  34. KIONG KL, Lin FY, Yao CMKL, Guo T, et al
    Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer.
    Cancer. 2020 Jul 24. doi: 10.1002/cncr.33103.
    PubMed     Abstract available


  35. SAITO Y, Hayashi R, Iida Y, Mizumachi T, et al
    Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national head and neck cancer registry of Japan.
    Cancer. 2020 Jul 10. doi: 10.1002/cncr.33062.
    PubMed     Abstract available


  36. KANG JJ, Wong RJ, Sherman EJ, Rybkin A, et al
    The 3 B's of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.
    Cancer. 2020 Jul 8. doi: 10.1002/cncr.33031.
    PubMed     Abstract available


  37. SCHUTTE HW, van den Broek GB, Steens SCA, Hermens RPMG, et al
    Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer.
    Cancer. 2020 Jul 7. doi: 10.1002/cncr.33037.
    PubMed     Abstract available


    June 2020
  38. HUENIKEN K, Douglas CM, Jethwa AR, Mirshams M, et al
    Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire.
    Cancer. 2020 Jun 30. doi: 10.1002/cncr.33032.
    PubMed     Abstract available


  39. BROUGHMAN JR, Xiong DD, Moeller BJ, Contrera KJ, et al
    Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Cancer. 2020;126:2784-2790.
    PubMed     Abstract available


  40. LEE AWM, Ngan RKC, Ng WT, Tung SY, et al
    NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32972.
    PubMed     Abstract available


  41. CAVALIERI S, Licitra L
    Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32971.
    PubMed    


  42. HUANG SH, O'Sullivan B, Su J, Ringash J, et al
    Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Cancer. 2020 Jun 1. doi: 10.1002/cncr.32968.
    PubMed     Abstract available


  43. LANG KUHS KA, Wood CB, Wiggleton J, Aulino JM, et al
    Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer.
    Cancer. 2020;126:2658-2665.
    PubMed     Abstract available


    May 2020
  44. SEIWERT TY, Kochanny S, Wood K, Worden FP, et al
    A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
    Cancer. 2020 May 4. doi: 10.1002/cncr.32929.
    PubMed     Abstract available


    April 2020
  45. BIGELOW EO, Blackford AL, Eytan DF, Eisele DW, et al
    Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls.
    Cancer. 2020;126:1793-1803.
    PubMed     Abstract available


  46. FULLERTON ZH, Butler SS, Mahal BA, Muralidhar V, et al
    Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status.
    Cancer. 2020;126:1424-1433.
    PubMed     Abstract available


  47. OLIVER JR, Lieberman SM, Tam MM, Liu CZ, et al
    Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma.
    Cancer. 2020;126:1413-1423.
    PubMed     Abstract available


    March 2020
  48. WILSON CL, Brinkman TM, Cook C, Huang S, et al
    Clinically ascertained health outcomes, quality of life, and social attainment among adult survivors of neuroblastoma: A report from the St. Jude Lifetime Cohort.
    Cancer. 2020;126:1330-1338.
    PubMed     Abstract available


  49. ZHAN KY, Puram SV, Li MM, Silverman DA, et al
    National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2020;126:1295-1305.
    PubMed     Abstract available


  50. CHEN FP, Huang XD, Lv JW, Wen DW, et al
    Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
    Cancer. 2020 Mar 3. doi: 10.1002/cncr.32770.
    PubMed     Abstract available


    February 2020
  51. MROZ EA, Patel KB, Rocco JW
    Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
    Cancer. 2020 Feb 21. doi: 10.1002/cncr.32742.
    PubMed     Abstract available


  52. KOCHANNY SE, Worden FP, Adkins DR, Lim DW, et al
    A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32762.
    PubMed     Abstract available


  53. BASAK SK, Bera A, Yoon AJ, Morselli M, et al
    A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32644.
    PubMed     Abstract available


    January 2020
  54. KHAN A, Mubdi N, Budnick A, Feldman DR, et al
    The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study.
    Cancer. 2020 Jan 3. doi: 10.1002/cncr.32698.
    PubMed     Abstract available


  55. FREITAG J, Wald T, Kuhnt T, Gradistanac T, et al
    Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2020;126:1856-1872.
    PubMed     Abstract available


  56. RODEN DF, Hobelmann K, Vimawala S, Richa T, et al
    Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery.
    Cancer. 2020;126:1873-1887.
    PubMed     Abstract available


  57. FAN M, Kang JJ, Lee A, Fan D, et al
    Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.
    Cancer. 2020;126:1905-1916.
    PubMed     Abstract available


    December 2019
  58. DZIEGIELEWSKI PT, McNeely ML, Ashworth N, O'Connell DA, et al
    2b or not 2b? Shoulder function after level 2b neck dissection: A double-blind randomized controlled clinical trial.
    Cancer. 2019 Dec 24. doi: 10.1002/cncr.32681.
    PubMed     Abstract available


  59. CHEN YY, Wang CC, Wu WT, Lai CH, et al
    Trajectories of returning to work and its impact on survival in survivors with oral cancer: A 5-year follow-up study.
    Cancer. 2019 Dec 6. doi: 10.1002/cncr.32643.
    PubMed     Abstract available


    November 2019
  60. NG SP, Ajayi T, Schaefer AJ, Pollard C 3rd, et al
    Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model.
    Cancer. 2019 Nov 14. doi: 10.1002/cncr.32597.
    PubMed     Abstract available


  61. THOMPSON-HARVEY A, Yetukuri M, Hansen AR, Simpson MC, et al
    Rising incidence of late-stage head and neck cancer in the United States.
    Cancer. 2019 Nov 13. doi: 10.1002/cncr.32583.
    PubMed     Abstract available


  62. KAWAKITA D, Abdelaziz S, Chen Y, Rowe K, et al
    Adverse respiratory outcomes among head and neck cancer survivors in the Utah Cancer Survivors Study.
    Cancer. 2019 Nov 13. doi: 10.1002/cncr.32617.
    PubMed     Abstract available


  63. LIU C, Guo T, Sakai A, Ren S, et al
    A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.
    Cancer. 2019 Nov 13. doi: 10.1002/cncr.32610.
    PubMed     Abstract available


    October 2019
  64. NOCON CC, Ajmani GS, Bhayani MK
    A contemporary analysis of racial disparities in recommended and received treatment for head and neck cancer.
    Cancer. 2019 Oct 3. doi: 10.1002/cncr.32342.
    PubMed     Abstract available


    September 2019
  65. LIN C, Cao SM, Chang ET, Liu Z, et al
    Chinese nonmedicinal herbal diet and risk of nasopharyngeal carcinoma: A population-based case-control study.
    Cancer. 2019 Sep 22. doi: 10.1002/cncr.32458.
    PubMed     Abstract available


  66. YOSHIDA EJ, Luu M, Mallen-St Clair J, Mita AC, et al
    Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32501.
    PubMed     Abstract available


  67. ARGIRION I, Zarins KR, Ruterbusch JJ, Vatanasapt P, et al
    Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United States.
    Cancer. 2019 Sep 16. doi: 10.1002/cncr.32517.
    PubMed     Abstract available


    August 2019
  68. AMENABAR JM, Torres-Pereira CC, Tang KD, Punyadeera C, et al
    Two enemies, one fight: An update of oral cancer in patients with Fanconi anemia.
    Cancer. 2019 Aug 7. doi: 10.1002/cncr.32435.
    PubMed     Abstract available


    July 2019
  69. SHAO D, Vogtmann E, Liu A, Qin J, et al
    Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32403.
    PubMed     Abstract available


  70. SASAKI CT, Doukas SG, Costa J, Vageli DP, et al
    Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications.
    Cancer. 2019 Jul 16. doi: 10.1002/cncr.32369.
    PubMed     Abstract available


    June 2019
  71. HADDAD R, Concha-Benavente F, Blumenschein G Jr, Fayette J, et al
    Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Cancer. 2019 Jun 27. doi: 10.1002/cncr.32190.
    PubMed     Abstract available


  72. KIM M, Kim BH, Kim JM, Kim EH, et al
    Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma.
    Cancer. 2019 Jun 19. doi: 10.1002/cncr.32166.
    PubMed     Abstract available


  73. PATEL SA, Qureshi MM, Dyer MA, Jalisi S, et al
    Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32292.
    PubMed     Abstract available


    May 2019
  74. PATIL VM, Noronha V, Joshi A, Agarwal J, et al
    A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32179.
    PubMed     Abstract available


  75. PARK A, Alabaster A, Shen H, Mell LK, et al
    Undertreatment of women with locoregionally advanced head and neck cancer.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32187.
    PubMed     Abstract available


  76. GRANT S, Kamal M, Mohamed ASR, Zaveri J, et al
    Single-item discrimination of quality-of-life-altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing.
    Cancer. 2019;125:1654-1664.
    PubMed     Abstract available


  77. LIN TA, Garden AS, Elhalawani H, Elgohari B, et al
    Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
    Cancer. 2019;125:1536-1546.
    PubMed     Abstract available


    April 2019
  78. ROLLO F, Pichi B, Benevolo M, Giuliani M, et al
    Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32152.
    PubMed     Abstract available


  79. TIAN S, Switchenko JM, Jhaveri J, Cassidy RJ, et al
    Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32115.
    PubMed     Abstract available


    March 2019
  80. FAKHRY C, Zhang Q, Gillison ML, Nguyen-Tan PF, et al
    Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.
    Cancer. 2019 Mar 26. doi: 10.1002/cncr.32025.
    PubMed     Abstract available


  81. BEITLER JJ, Switchenko JM, Dignam JJ, McDonald MW, et al
    Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx.
    Cancer. 2019;125:704-711.
    PubMed     Abstract available


  82. FARAJI F, Rettig EM, Tsai HL, El Asmar M, et al
    The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status.
    Cancer. 2019;125:761-769.
    PubMed     Abstract available


    February 2019
  83. NG SP, Pollard C 3rd, Berends J, Ayoub Z, et al
    Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.31983.
    PubMed     Abstract available


  84. LEE NCJ, Kelly JR, An Y, Park HS, et al
    Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32001.
    PubMed     Abstract available


    January 2019
  85. MONDACA S, Janjigian YY
    Application of positron emission tomography imaging to personalize esophagogastric cancer care.
    Cancer. 2019 Jan 22. doi: 10.1002/cncr.31940.
    PubMed    


  86. WINDON MJ, D'Souza G, Faraji F, Troy T, et al
    Priorities, concerns, and regret among patients with head and neck cancer.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31920.
    PubMed     Abstract available


  87. LIU APY, Hastings C, Wu S, Bass JK, et al
    Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31918.
    PubMed     Abstract available


  88. BEESLEY LJ, Hawkins PG, Amlani LM, Bellile EL, et al
    Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era.
    Cancer. 2019;125:68-78.
    PubMed     Abstract available


    December 2018
  89. JIANG C, Wang H, Xia C, Dong Q, et al
    A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31907.
    PubMed     Abstract available


  90. BADR H, Herbert K, Chhabria K, Sandulache VC, et al
    Self-management intervention for head and neck cancer couples: Results of a randomized pilot trial.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31906.
    PubMed     Abstract available


    November 2018
  91. CRACCHIOLO JR, Klassen AF, Young-Afat DA, Albornoz CR, et al
    Leveraging patient-reported outcomes data to inform oncology clinical decision making: Introducing the FACE-Q head and neck cancer module.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31900.
    PubMed     Abstract available


  92. EYTAN DF, Blackford AL, Eisele DW, Fakhry C, et al
    Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States.
    Cancer. 2018 Nov 16. doi: 10.1002/cncr.31800.
    PubMed     Abstract available


  93. GREALLY M, Ilson DH
    Neoadjuvant therapy for esophageal cancer: Who, when, and what?
    Cancer. 2018;124:4276-4278.
    PubMed    


    October 2018
  94. HARADA K, Pool Pizzi M, Baba H, Shanbhag ND, et al
    Cancer stem cells in esophageal cancer and response to therapy.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31697.
    PubMed    


  95. GUO R, Tang LL, Mao YP, Du XJ, et al
    Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Cancer. 2018 Oct 23. doi: 10.1002/cncr.31741.
    PubMed     Abstract available


  96. THAM T
    Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31819.
    PubMed    


  97. CHAN JYW, Huang WB, Liu DL
    Reply to Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31815.
    PubMed    


  98. BAUML JM, Vinnakota R, Anna Park YH, Bates SE, et al
    Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data.
    Cancer. 2018 Oct 20. doi: 10.1002/cncr.31816.
    PubMed     Abstract available


  99. XIANG M, Holsinger FC, Colevas AD, Chen MM, et al
    Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31708.
    PubMed     Abstract available


  100. BAUMAN JE, Duvvuri U, Thomas S, Gooding WE, et al
    Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31651.
    PubMed     Abstract available


  101. SABA NF, Mendenhall WM, Hutcheson K, Suarez C, et al
    Salvage Surgery for Squamous Cell Carcinoma of the Head and Neck in the Era of Immunotherapy: Is It Time to Clarify Our Guidelines?
    Cancer. 2018 Oct 5. doi: 10.1002/cncr.31717.
    PubMed    


    August 2018
  102. SARAFIM-SILVA BAM, Duarte GD, Sundefeld MLMM, Biasoli ER, et al
    Childhood Trauma Is Predictive for Clinical Staging, Alcohol Consumption, and Emotional Symptoms in Patients With Head and Neck Cancer.
    Cancer. 2018 Aug 6. doi: 10.1002/cncr.31597.
    PubMed     Abstract available


    June 2018
  103. GRABOYES EM, Ellis MA, Li H, Kaczmar JM, et al
    Racial and ethnic disparities in travel for head and neck cancer treatment and the impact of travel distance on survival.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31571.
    PubMed     Abstract available


    May 2018
  104. SOTO-PEREZ-DE-CELIS E, Sun CL, Tew WP, Mohile SG, et al
    Association between patient-reported hearing and visual impairments and functional, psychological, and cognitive status among older adults with cancer.
    Cancer. 2018 May 24. doi: 10.1002/cncr.31540.
    PubMed     Abstract available


  105. XIAO C, Beitler JJ, Higgins KA, Glazer T, et al
    Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31537.
    PubMed     Abstract available


  106. HO AS, Kim S, Tighiouart M, Mita A, et al
    Quantitative survival impact of composite treatment delays in head and neck cancer.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31533.
    PubMed     Abstract available


  107. WEISS JM, Grilley-Olson JE, Deal AM, Zevallos JP, et al
    Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31526.
    PubMed     Abstract available


    April 2018
  108. GUERRIERO MK, Redman MW, Baker KK, Martins RG, et al
    Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31407.
    PubMed     Abstract available


  109. TOTA JE, Engels EA, Madeleine MM, Clarke CA, et al
    Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31359.
    PubMed     Abstract available


    March 2018
  110. HU J, Bao C, Gao J, Guan X, et al
    Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31318.
    PubMed     Abstract available


    January 2018
  111. ZIMMARO LA, Sephton SE, Siwik CJ, Phillips KM, et al
    Depressive symptoms predict head and neck cancer survival: Examining plausible behavioral and biological pathways.
    Cancer. 2018 Jan 22. doi: 10.1002/cncr.31109.
    PubMed     Abstract available


  112. XIAO R, Ward MC, Yang K, Adelstein DJ, et al
    Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: A mechanism for increased mortality.
    Cancer. 2018 Jan 9. doi: 10.1002/cncr.31213.
    PubMed     Abstract available


  113. RAZZAGHI H, Saraiya M, Thompson TD, Henley SJ, et al
    Five-year relative survival for human papillomavirus-associated cancer sites.
    Cancer. 2018;124:203-211.
    PubMed     Abstract available


    December 2017
  114. DAHLSTROM KR, Anderson KS, Field MS, Chowell D, et al
    Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.
    Cancer. 2017;123:4886-4894.
    PubMed     Abstract available


  115. CHIN RI, Rao YJ, Hwang MY, Spencer CR, et al
    Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil.
    Cancer. 2017;123:4594-4607.
    PubMed     Abstract available


    November 2017
  116. ALI SM, Ross JS, Wang K
    Reply to Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays.
    Cancer. 2017 Nov 22. doi: 10.1002/cncr.31132.
    PubMed    


  117. LUI VWY, To KF, Lo KW
    Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays.
    Cancer. 2017 Nov 22. doi: 10.1002/cncr.31131.
    PubMed    


  118. ECONOMIDES MP, Amit M, Mahale PS, Hosry JJ, et al
    Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer.
    Cancer. 2017 Nov 17. doi: 10.1002/cncr.31146.
    PubMed     Abstract available


  119. PRINTZ C
    First person: Maura L. Gillison, MD, PhD: The researcher who found the link between the human papillomavirus and head and neck cancers continues to lead new discoveries in the field.
    Cancer. 2017;123:4307.
    PubMed    


  120. LANG KUHS KA, Kreimer AR, Trivedi S, Holzinger D, et al
    Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Cancer. 2017;123:4382-4390.
    PubMed     Abstract available


  121. GUPTA A, Sonis ST, Schneider EB, Villa A, et al
    Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31095.
    PubMed     Abstract available


  122. HOBAN CW, Beesley LJ, Bellile EL, Sun Y, et al
    Individualized outcome prognostication for patients with laryngeal cancer.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31087.
    PubMed     Abstract available


    October 2017
  123. HUANG WB, Chan JYW, Liu DL
    Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31031.
    PubMed     Abstract available


  124. BURTNESS B
    The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31059.
    PubMed    


  125. GLEBER-NETTO FO, Zhao M, Trivedi S, Wang J, et al
    Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31063.
    PubMed     Abstract available


  126. NELSON RA, Lai LL
    Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.
    Cancer. 2017;123:4013-4021.
    PubMed     Abstract available


  127. CAPARROTTI F, Huang SH, Lu L, Bratman SV, et al
    Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy.
    Cancer. 2017;123:3691-3700.
    PubMed     Abstract available


    September 2017
  128. SACCO AG, Cohen EE
    Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.30970.
    PubMed    


    August 2017
  129. ALBERGOTTI WG, Jordan J, Anthony K, Abberbock S, et al
    A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx.
    Cancer. 2017;123:3132-3140.
    PubMed     Abstract available


  130. ROBIN TP, Jones BL, Gordon OM, Phan A, et al
    A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.
    Cancer. 2017;123:3040-3049.
    PubMed     Abstract available


    April 2017
  131. D'SOUZA G, Robbins HA
    Sexual and relationship health among survivors of oropharyngeal or oral cavity squamous cell carcinoma.
    Cancer. 2017;123:1092-1094.
    PubMed    


    March 2017
  132. SINHA P, Haughey BH, Kallogjeri D, Spitznagel EL, et al
    The role of postoperative chemoradiation for oropharyngeal carcinoma: A critical appraisal revisited.
    Cancer. 2017;123:887-888.
    PubMed    


    January 2017
  133. COOPER JS, Fortpied C, Gregoire V, Le QT, et al
    The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited.
    Cancer. 2017;123:12-16.
    PubMed    


  134. COLLINS GS, Le Manach Y
    Nomograms need to be presented in full.
    Cancer. 2017;123:177-178.
    PubMed    


  135. CHOI HC, Xu W, Lee AW
    Reply to Nomograms need to be presented in full.
    Cancer. 2017;123:178-179.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: